{"id":"desidustat-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hyperuricemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PHD enzymes, desidustat prevents the degradation of HIF-α under normoxic conditions, leading to increased HIF stability and transcriptional activity. This results in upregulation of erythropoietin (EPO) and other HIF-target genes, promoting red blood cell production. This mechanism addresses anemia without requiring exogenous erythropoiesis-stimulating agents.","oneSentence":"Desidustat inhibits prolyl hydroxylase domain-containing protein (PHD) enzymes to stabilize hypoxia-inducible factor (HIF) and increase endogenous erythropoietin production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:37.247Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia in chronic kidney disease patients not on dialysis"},{"name":"Anemia in dialysis-dependent chronic kidney disease patients"}]},"trialDetails":[{"nctId":"NCT05515367","phase":"PHASE4","title":"A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)","status":"RECRUITING","sponsor":"Zydus Lifesciences Limited","startDate":"2023-04-20","conditions":"Chronic Kidney Diseases, Anemia of Chronic Kidney Disease","enrollment":1004},{"nctId":"NCT04215120","phase":"PHASE3","title":"Desidustat in the Treatment of Anemia in CKD on Dialysis Patients","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2020-01-04","conditions":"Chronic Kidney Disease Stage 5 on Dialysis","enrollment":392},{"nctId":"NCT04012957","phase":"PHASE3","title":"Desidustat in the Treatment of Anemia in CKD","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2019-07-20","conditions":"Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4","enrollment":588}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Desidustat Oral Tablet","genericName":"Desidustat Oral Tablet","companyName":"Zydus Lifesciences Limited","companyId":"zydus-lifesciences-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desidustat inhibits prolyl hydroxylase domain-containing protein (PHD) enzymes to stabilize hypoxia-inducible factor (HIF) and increase endogenous erythropoietin production. Used for Anemia in chronic kidney disease patients not on dialysis, Anemia in dialysis-dependent chronic kidney disease patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}